Predictive Value of Serum Heat Shock Protein 90α on the Prognosis of Patients with Lung Adenocarcinoma

Figures & data

Table 1 Patient Baseline Characteristics and Correlations with HSP90α (n=228)

Variables	All patients (N=228)		HSP90α< 93.76 (N=136)		HSP90α ≥ 93.76 (N=92)		X^2	P value
	N	%	N	%	N	%
Age (years)	62.04±9.55		62.49±9.52		61.37±9.55		1.155	0.283
Sex
Male	74	32.46	34	25.00	40	43.48	8.547	0.003*
Female	154	67.54	102	75.00	52	56.52
Smoke
Yes	76	33.33	38	27.94	38	41.30	5.508	0.019*
No	152	66.67	98	72.06	54	58.70
T
T1	16	7.02	16	11.76	0	0.00	24.084	<0.001*
T2	98	42.98	68	50.00	30	32.61
T3	106	46.49	48	35.29	58	63.04
T4	8	3.51	4	2.94	4	4.35
N
N0	70	30.70	58	42.65	12	13.04	27.546	<0.001*
N1	96	42.11	48	35.29	48	52.22
N2	46	20.18	26	19.12	20	21.74
N3	16	7.01	4	2.94	12	13.04
M
M0	160	70.18	116	85.29	44	47.83	37.550	<0.001*
M1	68	29.82	20	14.71	48	52.17
TNM stage
I	14	6.14	14	10.29	0	0	49.398	<0.001*
II	62	27.19	50	36.76	12	13.04
III	82	35.96	52	38.24	30	32.61
IV	70	30.70	20	14.71	50	54.35
Degree of differentiation
Well/moderate	88	38.60	72	52.94	16	17.39	3.652	0.056
Poor/undifferentiated	140	61.40	64	47.06	76	82.61
CEA
< 5 ng/mL	18	7.89	10	7.35	8	8.70	7.075	0.008*
≥ 5 ng/mL	210	92.11	126	92.65	84	91.30
NSE
< 15 ng/mL	36	15.79	30	22.06	6	6.52	23.369	<0.001*
≥ 15 ng/mL	192	84.21	106	77.94	86	93.48
CYFA21-1
< 4 ng/mL	33	14.47	22	16.18	11	11.96	16.472	<0.001*
≥ 4 ng/mL	195	85.53	114	83.82	81	88.04

Note: * as p<0.05.

Table 2 Comparative Univariate Survival Analyses of 228 Patients with LUAD

Univariate analysis	Progression-Free Survival		Overall Survival
	HR (95% CI)	P value	HR (95% CI)	P value
Age (years)		0.101		0.325
<65	1		1
≥65	0.790 (0.509, 1.074)		1.194 (0.838, 1.702)
Sex		<0.001*		<0.001*
Male	1		1
Female	0.566 (0.421, 0.761)		0.478 (1.505, 3.071)
Smoke		<0.001*		<0.001*
Yes	1		1
No	1.972 (1.464, 2.567)		2.150 (1.082, 2.701)
T		<0.001*		<0.001*
T1, 2	1		1
T3, 4	2.505 (1.720, 2.442)		2.413 (1.662, 2.764)
N		<0.001*		0.011*
N0	1		1
N1, 2, 3	33.699 (18.266, 62.712)		1.686 (1.125, 2.527)
M		<0.001*		<0.001*
M0	1		1
M1	4.907 (3.744, 6.431)		11.127 (7.082, 17.482)
TNM stage		<0.001*		<0.001*
I, II	1		1
III, IV	2.014 (1.600, 2.534)		4.089 (2.012, 6.401)
Degree of differentiation		<0.001*		0.007*
Well/moderate	1		1
Poor/undifferentiated	0.517 (0.386, 0.694)		0.605 (0.420, 0.870)
CEA		0.426		0.012*
<5 ng/mL	1		1
≥5 ng/mL	1.212 (0.746, 1.970)		2.655 (1.236, 5.701)
NSE		0.001*		0.000*
<15 ng/mL	1		1
≥15 ng/mL	3.468 (2.193, 5.486)		4.237 (2.064, 8.710)
CYFA21-1		0.038*		0.012*
<4 ng/mL	1		1
≥4 ng/mL	1.510 (1.023, 2.229)		2.040 (1.17, 3.558)
HSP90α		<0.001*		<0.001*
<93.76 ng/mL	1		1
≥93.76 ng/mL	0.323 (0.236, 0.440)		0.276 (0.192, 0.397)

Note: * as p<0.05.

Table 3 Comparative Multivariate Survival Analyses of 228 Patients with LUAD

Univariate Analysis	Progression-Free Survival			Overall Survival
	HR (95% CI)		P value	HR (95% CI)	P value
Sex			0.796		0.371
Male	1			1
Female	1.112 (0.498, 2.482)			1.559 (0.590, 4.120)
Smoke			0.286		0.107
Yes	1			1
No	1.420 (0.746, 2.705)			2.211 (0.843, 5.797)
T			0.001*		0.333
T1, 2	1			1
T3, 4	2.526 (1.640, 3.892)			1.2063 (0.826, 1.760)
N			0.235		0.000*
N0	1			1
N1, 2, 3	1.215 (0.881, 1.667)			0.341 (0.190, 0.611)
M			0.540		<0.001*
M0	1			1
M1	1.129 (0.766, 1.666)			6.772 (4.004, 11.453)
TNM stage			<0.001*		0.005*
I, II	1			1
III, IV	18.461 (9.854, 34.588)			2.924 (1.391, 6.147)
Degree of differentiation			0.004*		0.210
Well/moderate	1			1
Poor/undifferentiated	0.673 (0.467, 0.868)			0.776 (0.523, 1.513)
CEA			_		0.038*
<5 ng/mL	_			1
≥5 ng/mL	_			2.512 (1.050, 6.010)
NSE			0.065		0.638
<15 ng/mL	1			1
≥15 ng/mL	1.683 (0.966, 2.932)			0.803 (0.323, 1.999)
CYFA21-1			0.303		0.207
<4 ng/mL	1			1
≥4 ng/mL	0.799 (0.522, 1.224)			1.488 (0.803, 2.760)
HSP90α			0.015*		<0.001*
< 93.76 ng/mL	1			1
≥ 93.76 ng/mL	0.705 (0.501, 0.922)			0.312 (0.201, 0.484)

Note: * as p<0.05.

Figure 1 K-M curves for PFS and OS of HSP90α in 228 LUAD patients. (A) K-M curve for PFS in high and low level HSP90α patients with LUAD; (B) K-M curve for OS in high and low level HSP90α patients with LUAD.

Figure 2 Relationship between HSP90α and TNM stage in 228 LUAD patients.

Figure 3 Correlation of HSP90α1 with CEA and prognosis of HSP90α combined with CEA in 228 LUAD patients. (A) Correlation analysis between the expression levels of HSP90α and CEA in in the serum of patients with LUAD; (B) The K–M curve and Log rank test for OS in different level HSP90α patients with LUAD.